Resected squamous cell carcinoma of the head and neck research hub

A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin

This study looks at a new medicine called xevinapant, given with radiotherapy, for people who have had surgery for head and neck cancer. It compares this treatment to radiotherapy with a dummy medicine, to see if xevinapant helps prevent the cancer from coming back.